ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).

Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia.

This analysis combined cardiovascular outcomes data from two phase 3 lipid studies: the Brooklyn study (354 patients with heterozygous familial hypercholesterolemia) and the Broadway study (over 2,500 high cardiovascular risk individuals). Both 12-month studies evaluated 10mg obicetrapib versus placebo in patients with elevated LDL cholesterol despite statin therapy.

Findings showed a 32% reduction in cardiovascular events with obicetrapib, with greater benefit emerging in the latter half of treatment (55% risk reduction from months 6-12), alongside consistent reductions in both LDL cholesterol and lipoprotein(a) levels.

Interview Questions:
1. What were the objects of the pooled mace analysis? 
2. Could you tell us more about the study design and patient population? 
3. What were your key outcomes?
4. How might these findings impact clinical practice for patients with atherosclerotic cardiovascular disease who remain at high risk despite optimal lipid-lowering therapy?
5. What are the implications of these results for the future of CETP inhibition in cardiovascular prevention?

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview conducted by Radcliffe Cardiology.